Principal Financial Group Inc. grew its holdings in NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 2.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 639,411 shares of the medical research company’s stock after acquiring an additional 16,562 shares during the period. Principal Financial Group Inc. owned about 0.50% of NeoGenomics worth $6,068,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in shares of NeoGenomics by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 14,239,887 shares of the medical research company’s stock valued at $234,673,000 after acquiring an additional 195,793 shares during the last quarter. Greenhouse Funds LLLP lifted its holdings in shares of NeoGenomics by 5.3% in the 4th quarter. Greenhouse Funds LLLP now owns 4,701,897 shares of the medical research company’s stock worth $77,487,000 after acquiring an additional 237,491 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of NeoGenomics by 2.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 3,436,858 shares of the medical research company’s stock worth $56,645,000 after purchasing an additional 78,211 shares during the period. First Light Asset Management LLC grew its holdings in NeoGenomics by 3.0% during the 4th quarter. First Light Asset Management LLC now owns 3,167,585 shares of the medical research company’s stock valued at $52,202,000 after purchasing an additional 91,030 shares during the last quarter. Finally, Segall Bryant & Hamill LLC raised its position in NeoGenomics by 11.6% in the 4th quarter. Segall Bryant & Hamill LLC now owns 2,113,822 shares of the medical research company’s stock worth $34,836,000 after purchasing an additional 220,415 shares during the period. Hedge funds and other institutional investors own 98.50% of the company’s stock.
NeoGenomics Stock Up 0.1%
NEO stock opened at $6.91 on Thursday. The stock has a market capitalization of $889.32 million, a PE ratio of -11.33 and a beta of 1.63. The company has a quick ratio of 1.95, a current ratio of 2.05 and a debt-to-equity ratio of 0.38. NeoGenomics, Inc. has a 52 week low of $6.08 and a 52 week high of $19.12. The firm has a 50 day moving average of $7.46 and a 200 day moving average of $10.18.
Analysts Set New Price Targets
NEO has been the topic of several research analyst reports. Piper Sandler set a $12.00 price objective on NeoGenomics and gave the company an “overweight” rating in a research report on Tuesday, May 6th. Guggenheim started coverage on shares of NeoGenomics in a report on Thursday, May 15th. They set a “neutral” rating on the stock. Leerink Partnrs lowered shares of NeoGenomics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 30th. Leerink Partners downgraded shares of NeoGenomics from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $25.00 to $9.00 in a research note on Wednesday, April 30th. Finally, Morgan Stanley decreased their price objective on NeoGenomics from $17.00 to $10.00 and set an “equal weight” rating for the company in a research note on Thursday, May 1st. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $13.83.
Read Our Latest Stock Report on NeoGenomics
Insider Transactions at NeoGenomics
In other news, COO Warren Stone acquired 5,700 shares of the firm’s stock in a transaction on Monday, May 12th. The stock was acquired at an average price of $8.58 per share, for a total transaction of $48,906.00. Following the completion of the transaction, the chief operating officer owned 108,280 shares in the company, valued at approximately $929,042.40. The trade was a 5.56% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Michael Aaron Kelly bought 5,000 shares of the stock in a transaction dated Tuesday, May 27th. The shares were purchased at an average cost of $7.60 per share, for a total transaction of $38,000.00. Following the completion of the purchase, the director owned 5,000 shares in the company, valued at approximately $38,000. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 70,600 shares of company stock valued at $550,438. 2.40% of the stock is owned by insiders.
NeoGenomics Profile
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
See Also
- Five stocks we like better than NeoGenomics
- What is MarketRank™? How to Use it
- 3 Stocks to Cushion Your Portfolio This Earnings Season
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- This Fund Manager Says You Should Get Out of Tesla and Apple—Now
- ESG Stocks, What Investors Should Know
- JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.